InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
25%
T+90 mean return
-23.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Hung David, Director. Insider active across 3 companies, notably NovoCure Ltd. Aggregated, 7 disclosures have been logged. Split: 1 buy · 1 sell. Total volume traded: €301k. History available since 9 June 2021. The latest transaction was filed on 4 April 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations7 total
200,000 shares@ US$1.6636100.0% of flowClass A Common StockSEC:0001415889-25-010446:0
Ideal exit: 30 Dec 2025 (T+270)
4,053 shares0Restricted Stock UnitsSEC:0001562180-24-004768:0
368,408 shares0Class A Common StockSEC:0001209191-23-014890:0
2,427 shares0Restricted Stock UnitsSEC:0001645113-22-000054:0
814 shares0Restricted Stock UnitsSEC:0001645113-21-000075
814 shares0Restricted Stock UnitsSEC:0001645113-21-000075:0
6,350 sharesCommon StockSEC:0001209191-16-096111:0
7 of 7 declarations
About Hung David
David Hung is a Director at NovoCure Ltd, a biotechnology company developing treatments for cancer. With extensive expertise in the healthcare sector, he contributes to the company's strategy and governance, ensuring that NovoCure's objectives are met while adhering to ethical and regulatory standards.
